All studies
Active not recruitingPHASE2INTERVENTIONAL

A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema

Hereditary angioedema (HAE) is a rare genetic condition that causes sudden, painful swelling in different parts of the body, such as the hands, feet, face, gut, or throat. This Phase 2 clinical trial is testing a new preventive medicine called STAR-0215. The main goal is to find out how safe STAR-0215 is and how well it stops swelling attacks when taken over a longer period. The trial is open to adults aged 18 and older with Type 1 or Type 2 HAE. This includes people who took part in an earlier study of the drug, as well as those who have never tried it before. Participants will receive repeat doses of STAR-0215 for up to five years. Throughout the study, doctors will closely monitor each person to see if the medicine offers lasting protection and helps improve day-to-day life.

At a glance

Status
Active not recruiting
Phase
PHASE2
Sponsor
Astria Therapeutics, Inc.
Enrolment target
56
Start
26 Sep 2023
Estimated completion
01 Mar 2031

What is this study about?

Hereditary angioedema (HAE) is a lifelong genetic condition that causes blood vessels to leak fluid into nearby tissues. This leads to unpredictable swelling attacks that can be very painful and disruptive. If the swelling happens in the throat, it can even become an emergency. Finding reliable treatments that can prevent these attacks before they start is a key priority for doctors and patients alike.

This study focuses on an experimental medicine called STAR-0215. It is designed to act as a preventative treatment, meaning it aims to stop attacks from happening in the first place rather than treating them after they begin. Researchers have already started testing STAR-0215, but they now need to understand how the body handles the medicine over a much longer timeframe.

Over the course of up to five years, researchers will gather vital information about the safety of repeat doses and how well the treatment prevents attacks over time. Long-term studies like this are crucial for rare diseases, as they provide the evidence needed to show whether a new therapy is safe and effective for ongoing, everyday use.

Key takeaways

  • Tests an experimental preventative medicine called STAR-0215 for hereditary angioedema.
  • Open to adults aged 18 and older with Type 1 or Type 2 HAE.
  • Participants may receive treatment for up to five years to assess long-term safety.
  • Welcomes both new participants and those who took part in the earlier STAR-0215 study.
  • Taking part is completely voluntary and you can leave at any time.

Who may be eligible?

This trial is open to adults aged 18 and over who have a confirmed diagnosis of Type 1 or Type 2 hereditary angioedema. You may be able to join if you took part in the previous STAR-0215 trial, or if you have never received this study medicine before.

You will not be able to take part if you have other types of swelling conditions, such as swelling linked to hives or Type 3 HAE. Because certain medicines can trigger attacks or interfere with the study, you cannot join if you have recently taken blood pressure medicines called ACE inhibitors, or therapies containing oestrogen (such as certain contraceptive pills or HRT).

You also cannot join if you have recently taken androgen steroids, or certain other preventative HAE drugs like lanadelumab or berotralstat, without an agreed break beforehand. The study doctor can check the timing of your current medications to see if you qualify.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am at least 18 years old.
  2. I have been diagnosed by a doctor with Type 1 or Type 2 hereditary angioedema.
  3. I do not have swelling caused by hives (urticaria) or Type 3 HAE.
  4. I have not recently used ACE inhibitor blood pressure pills or medicines containing oestrogen.
  5. I am willing to attend regular clinic check-ups over a long-term period.
Answer every question to see your result.

What does participation involve?

Taking part in this trial involves receiving repeat doses of the study medicine, STAR-0215, over a period of up to five years. You will need to visit a study clinic regularly so the medical team can check on your health and give you your treatment. During these visits, the team will perform routine tests, such as taking blood and urine samples, checking your vital signs, and doing physical examinations. You will also be asked to keep a record of any swelling attacks you experience between visits. The trial team will support you throughout the entire study to monitor how you are feeling.

Potential risks and benefits

Taking part may help reduce how often you get swelling attacks, but there is no guarantee that the medicine will work for you. By joining, you will also be helping doctors learn more about managing HAE, which could benefit others in the future. As with any new medicine, there is a risk of side effects, such as pain or redness where the injection is given, or other unexpected reactions. Your safety is closely tracked at every visit. Taking part is completely your choice, and you are free to leave the trial at any point without it affecting your normal medical care.

Locations (22)

  • Allervie Clinical Research
    Verified postcode
    Birmingham, United States
  • Medical Research of Arizona a Division of Allergy, Asthma & Immunology Associates, LTD
    Verified postcode
    Scottsdale, United States
  • Acuro Research
    Verified postcode
    Little Rock, United States
  • UC San Diego US HAEA Angioedema Center
    Verified postcode
    San Diego, United States
  • Raffi Tachdjian MD, Inc
    Verified postcode
    Santa Monica, United States
  • Allergy & Asthma Clinical Research
    Verified postcode
    Walnut Creek, United States
  • Institute for Asthma and Allergy, PC
    Verified postcode
    Chevy Chase, United States
  • Massachusetts General Hospital
    Verified postcode
    Boston, United States
  • Washington University School of Medicine
    Verified postcode
    St Louis, United States
  • Optimed Research
    Verified postcode
    Columbus, United States
  • Penn State Health Milton S. Hershey Medical Center
    Verified postcode
    Hershey, United States
  • AARA Research Center
    Verified postcode
    Dallas, United States

Common questions

What is the main purpose of this trial?

The study aims to see how safe STAR-0215 is and how well it prevents swelling attacks when taken regularly for up to five years.

Do I have to have taken STAR-0215 before to join?

No. The trial welcomes people who were in an earlier study of STAR-0215, as well as people who have never received the medicine before.

Will I have to stop my current HAE medications?

Certain long-term preventative treatments cannot be used during the trial. The study team will explain whether you need a break from your usual medicines and what rescue treatments you can use for sudden attacks.

Can I leave the study early if I want to?

Yes. Joining a clinical trial is entirely voluntary. You can stop taking part at any time, for any reason, and your regular doctor will continue your standard care.

Does it cost anything to take part?

No. The study treatment and all trial-related medical tests are provided free of charge, and trial visits are covered by the study organisers.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.